Oral aprepitant , a neurokinin-1 receptor antagonist , is recommended in combination with other anti-emetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults , but its efficacy and safety in paediatric patients are unknown .